Bosentan and Sitaxsentan
Endothelin receptor antagonists
Randomized controlled trials of oral endothelin receptor antagonists
| Trial | Channick et al. 2001 | Rubin et al. 2002 | Barst et al. 2002 |
| Prostanoid | Bosentan | Bosentan | Sitaxsentan |
| Patients (n) | 32 | 213 | 178 |
|
Etiology of PH |
85 / 15 / 0 0 / 0 / 0 |
70 / 30 / 21 0 / 0 / 0 |
53 / 24 / 24 0 / 0 / 0 |
| NYHA II / II / IV (%) | 0 / 100 / 0 | 91 / 9 / 0 | 33 / 66 / 1 |
| Duration (m) | 3 | 4 | 3 |
| Primary endpoint | 6-MW + NYHA |
6-MW | Peak VO2 |
| Improvement in 6-MW (m) compared to controls | +76 | +44 | +34 |
| Improvement in other endpoints | Hemodyn, NYHA Clinical events |
NYHA Clinical events |
|
| Side effects (n) | Elevated transaminases |
Elevated transaminases |
Elevated transaminases |